Pimavanserin, a new generation 5-HT2A selective antagonist, has been clinically tested as an antipsychotic in Parkinson’s disease and schizophrenia; its pharmacokinetic properties, safety and tolerability have been characterized in humans [112]. The gene discussed is HTR2A; the disease is schizophrenia.